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Abstract 
Background: Many studies on the impact of systemic lupus erythematosus or lupus have identified patient travel 
costs as being problematic. We administered a survey that examined the impact of self-rated travel burden on lupus 
patients. The systemic lupus erythematosus travel burden survey included 41 patients enrolled in the systemic lupus 
erythematosus database project at the Medical University of South Carolina.
Results: Most participants reported that travel caused medications to be discontinued or appointments to be 
missed. In unadjusted logistic regressions of the relationship between these outcomes and medical travel burden, 
both distance to rheumatologists and time to lupus medical care were significant.
Conclusions: Our findings suggest that more research is needed to examine the influence of travel burden among 
this population, but data from this report could help to inform physicians, academic researchers, and other health 
professionals in South Carolina and other areas with significant rural populations on how travel burden may impact 
patients receiving care for lupus and provide an opportunity for the development of interventions aimed at assisting 
lupus patients with management of stressors related to travel burden.
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Background
Systemic lupus erythematosus (SLE) is a complicated dis-
ease to diagnose and treat, and the associated symptoms 
can be mentally and physically devastating for a patient 
[1, 2]. For many patients, these problems are magnified 
by the travel burdens they must endure. Travel burdens 
that SLE patients experience are largely due to the costs 
of driving to doctor’s visits, but this is multiplied by the 
fact that patients may have to visit a physician many 
times before being correctly diagnosed [3]. Addition-
ally, once they have been correctly diagnosed, they will 
most likely need to see a specialist or multiple special-
ists [4]. In many cases, specialists are many miles away or 
the method of transportation that the patient has access 
to takes extensive amounts of time to get them there. 
Travel burden also encompasses barriers to care due to 
the negative impact that the disease can have on a SLE 
patient’s ability to access care [5]. Along with the distance 
and time it may take to get to a provider, travel burden 
may also include the pain associated with traveling to and 
from the doctor’s office and/or pharmacy locations [6, 7] 
as well as difficulty finding someone that will accompany 
them.
Disease impact of SLE has been studied extensively, 
including aspects of employment and the impact of 
SLE on medical and non-medical costs [8–12]. Many 
of these studies have identified patient travel costs as 
being problematic, eluding to negative impacts of social 
determinants of health. SLE patients are employed at a 
lower rate than the general population [13], which fur-
ther exacerbates the problem. However, no studies have 
explicitly sought to examine ways to mediate the adverse 
influence of social determinants of heath on disease out-
comes, especially regarding the concept of travel burden 
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[8, 14–21]. The current study administered a validated 
survey and obtained baseline data to examine self-rated 
travel burden and characterize geographic accessibility of 
facilities most utilized by SLE patients in South Carolina.
Methods
Development and validation of the SLEOTB survey
The systemic lupus erythematosus observations of travel 
burden (SLEOTB) project developed a scale for meas-
uring potential travel burden by conduct preliminary 
interviews to gain baseline knowledge of travel burden 
experienced by SLE patients in South Carolina, develop-
ing a survey instrument that to characterize observations, 
and pre-testing the survey through cognitive interview-
ing sessions. More detailed information on develop-
ment of the survey tool-the background, literature search 
strategy applied, results of qualitative studies performed, 
and pre-testing for usability-is reported elsewhere [22]. 
For a community perspective on issues of travel burden 
(e.g., costs of travel, health care impacts of travel burden, 
visitation frequency for various health care needs, etc.), 
individual interviews were conducted with ten (10) SLE 
patients enrolled in the SLE Database Project at the Med-
ical University of South Carolina (MUSC). Patients were 
randomly selected from the over 1000 SLE patients cur-
rently being followed at MUSC. A coding tree was devel-
oped to assist with coding of this data. Interviews were 
coded using NVivo software (Qualitative Solutions and 
Research, Pty Ltd, Victoria, Australia), a qualitative anal-
ysis research tool. Knowledge gained through the prelim-
inary interviews assisted in determining which categories 
of analysis from the preliminary interviews still held valid 
for the construction of the survey.
Major focus areas of the initial survey instrument were: 
(1) travel patterns for health care; (2) perceptions of travel 
burden for health care; (3) perception of discrimination 
and its impact on healthcare utilization (pooled from 
two validated sources-reactions to race module from the 
behavioral risk factor surveillance system [23, 24] and 
Victoroff’s Oppression Questionnaire [25]); and (4) per-
ceptions of how travel burden impacts disease manage-
ment and seeking health. To ensure the validity of the 
survey instrument, cognitive interviews were conducted 
with 15 randomly selected participants from the MUSC 
SLE Database who did not participated in the preliminary 
interviews. Cognitive interviewing has been shown to 
improve survey questionnaires [26–30]. In order to fur-
ther refine data on thematic issues relevant and specific 
to the types of self-rated travel burden that SLE patients 
in South Carolina experience across various socio-eco-
nomic strata, the cognitive interviews were analyzed 
using the cultural consensus model [31–34]. The cultural 
consensus model is a recent innovation in ethnographic 
methods that has been shown to be sensitive to intra-
cultural diversity as well as effects of stressors by social 
and cultural context [35]. Cultural consensus modeling 
was performed using Anthropac software (Columbia, 
Anakytic Technologies).
The resulting survey instrument assesses the impact 
that self-rated travel burden has on SLE patients regard-
ing: (1) visitation frequency for primary care/rheumatol-
ogist/immunologist; (2) participation in clinical trials; (3) 
non-health related issues; and (4) how self-rated travel 
burden compares across urban/rural divides. The sur-
vey also includes questions concerning quality of life 
measures, costs for travel to health care, socio-demo-
graphic information, estimated time spent for travel to 
healthcare, and preferred mode of transport. Questions 
contained in the 55-item questionnaire are structured 
in a likert-scale manner, for measuring the strength of 
responses. Each component of the survey also provides 
space for open-ended response, allowing more in-depth 
responses and giving participants the opportunity to pro-
vide additional information they may deem relevant.
Patients and entry criteria
Patients invited for survey administration were SLE 
patients attending rheumatology clinics at MUSC. All 
SLE patients met at least four components of the 1997 
American College of Rheumatology (ACR) revised cri-
teria for SLE [36], were 18  years of age or older, and 
were residing in South Carolina at the time of the study. 
Patients invited to participate in the proposed study were 
lupus patients participating in a longitudinal observa-
tional web-based SLE Database at MUSC. There were 
402 patients with lupus enrolled in the Database dur-
ing enrollment in this study. Patients in the Database 
were characterized longitudinally for disease activity and 
quality of life. As part of the informed consent process, 
participants agreed to future re-contact regarding other 
research studies. MUSC’s SLE cohort is geographically 
diverse, representing more than 60 South Carolina, Geor-
gia, and North Carolina counties. Of the 402 patients 
with lupus, 336 were African–American. This study was 
approved by the University of South Carolina (USC) and 
MUSC Institutional Review Boards and written consent 
was obtained prior to data collection.
Recruitment
For the current study, a link to a description of the study 
was placed on the MUSC lupus erythematosus (MUS-
CLE) group’s website and their listservs were used to 
email potential participants. Recruitment letters were 
also mailed and phone calls made to MUSC SLE data-
base participants, and flyers were posted in correspond-
ing lupus clinics. Survey administration was offered to 
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participants in the most convenient format for them. This 
included telephone, online, or in-person administration. 
Patients were asked during recruitment which method 
they preferred. An online-version of the instrument was 
developed and made available on MUSC’s Research Elec-
tronic Data Capture (REDCap) system, a secure, web-
based application designed exclusively to support data 
capture for research studies [37, 38]. Target enrollment 
for the survey was 148 participants. Although we were 
only able to secure roughly 28 % of participants from the 
original target, this relatively small sample should not 
have any impact on findings as SLE patients can be dif-
ficult to enroll in studies in general [39–41]. While the 
survey instrument obtained both qualitative and meas-
ures more readily handled with quantitative analyses, this 
paper focuses on quantitative analyses. For a review of 
qualitative work in this area, please see Ortiz, Flournoy-
Floyd, & Williams, 2015 [42].
Measures
The main variables assessed to examine health-related 
travel burden among SLE patients included travel time (in 
minutes) to lupus-associated medical care, and distance 
(in miles) to rheumatologists of lupus patients. To char-
acterize travel burden more broadly, participants were 
asked to rate several domains in which travel could pro-
duce burden: (1) difficulty keeping appointments; (2) dif-
ficulty with general medical care travel; (3) difficulty with 
primary care travel (travel to/from primary care physi-
cians); and (4) difficulty with rheumatologist travel (travel 
to/from rheumatologist). In distinguishing between 
travel for various aspects related to lupus patients care, 
it was our intent to be able to isolate specific travel bur-
den for rheumatologist considering this subspecialty is 
vitally important for lupus patients. Moreover, being able 
to assess travel in the domains of general medical travel 
(e.g., travel for medications) and travel for primary care 
allows us to more thoroughly characterize travel burden. 
Response options for each of these measure was a likert 
scale (1, very difficult; 2, difficult; 3, neither; 4, easy; 5, 
very easy). All measures rely on self-reported data from 
patients participating in this survey. We utilized four out-
come measures to characterize travel burden: (1) whether 
travel affected appointments (yes/no); (2) whether travel 
caused medications to be discontinued (yes/no), (3) 
whether medical transportation increased stress (yes/no), 
and (4) number of appointments missed due to trans-
portation problems in the past year (count measure). 
Additionally, we control for several sociodemographic 
characteristics which have been shown to be impactful 
along the casual pathway in contributing to stress among 
lupus: (1) race (white, black); (2) age (in years); (3) gen-
der (male/female); (4) educational attainment (equal to 
or less than high diploma or equivalent/college degree or 
higher); (5) employment status (yes/no); self-rated health 
status (good/fair); annual household income (<$15,000; 
$15,000–$60,000; ≥$60,000); marital status (married, 
never married, other).
Data analysis
Input of data from telephone, online, and in-person 
surveys was completed throughout survey administra-
tion, and data was exported from the REDCap system 
in an excel format and manipulated using SAS statisti-
cal software. Survey data was analyzed utilizing statis-
tical methods most appropriate for the sample size and 
descriptive statistics generated. First, we provide soci-
odemographic characteristics of participants. Then we 
describe travel burden by using measures to characterize 
various domains in which travel could produce burden by 
presenting descriptive statistics (Tables 2, 3, 4). For group 
comparisons of the interactions of travel burden and per-
sonal attitudes about travel burden, the Kruskal–Wallis 
test was applied. In order to investigate the association 
between travel burden and medical care, we focused 
on our four primary variables. For (1) travel affected 
appoints, (2) whether travel caused medications to be 
discontinued and (3) whether medical transportation 
increased stress we utilized logistic regression models. 
For the last outcome measure, number of appointments 
missed as a result of transportation problems in the past 
year, we utilized Poisson regression models. To further 
study the relationship between medical travel burden 
and selected outcomes (medication discontinuation and 
missed appointments) after adjusting for possible vari-
ables including education level, employment status, self-
valuated health status, annual household income and 
marital status, multivariable logistic or Poisson regres-
sion models were constructed.
Results
A total of 41 patients participated, and 39 completed the 
survey, corresponding to an approximate 28 % response 
rate. Table 1 summarizes demographic characteristics of 
participants. Among all participants, the average age is 
43.15 (range 23–75), 89.2 % are female, 65.0 % are Afri-
can American, 76.3  % patients had an education level 
of college or higher; about half (53.9  %) of participants 
were currently employed; 70 % perceive their health sta-
tus as ‘good’; about half (48.7  %) of the patients had an 
annual household income between $15,000 and $60,000; 
and about half (51.7 %) of survey participants were mar-
ried. Most patients (92.3  %) currently had health insur-
ance. About a quarter of participants (25.7  %) reported 
Medicaid as their primary insurance provider, and 26.9 % 
had Medicare as their primary insurance provider. Only 
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23.1 % of participants reported that their insurance cov-
ered medical transportation. Table  2 shows that the 
mean travel time to lupus-associated medical care was 
approximately 57 min (ranging from 4 to 150 min), and 
the average distance to rheumatologists was approxi-
mately 53 miles (ranging from 4 to 200 miles).
Table  3 describes participants’ attitudes toward medi-
cal care travel. 30.6  % of participants considered it easy 
to keep medical appointments, compared with 33.3 % of 
participants who reported keeping appointments as dif-
ficult. 42.5  % of participants described their travel for 
medical care as easy, compared with 37.5 % who reported 
it as difficult. Regarding rheumatologist travel, 42.5 % of 
participants felt travel to their rheumatologist was easy, 
while 40  % of participants found it difficult. This trend 
was more pronounced with respect to primary care 
travel. 62.5 % of participants felt travel for primary care 
purposes was easy, while 20  % of participants found it 
difficult.
Table  4 shows that 35.9  % of participants felt that 
travel affected whether they were able to keep appoint-
ments, 12.8  % of participants reported discontinu-
ing medications as a result of travel issues, and 66.7  % 
reported feeling more stressed as a result of medical 
care transportation. Number of medical appointments 
missed during the last year due to transportation issues 
ranged from 0 to 5 appointments across all participants, 
but more than half of them (55.3 %) had not missed any 
appointments.
Further investigation of the interactions of travel bur-
den and personal attitudes toward travel burden revealed 
that the distance to rheumatologists, for patients who 
reported that travel affected their appointments, was sig-
nificantly longer (P 0.047 in Fig.  1a) and they reported 
significantly longer time to lupus-associated medical care 
(P 0.01 in Fig.  1b) compared with those who reported 
that travel did not affect their appointments. Those who 
reported that medical care transportation increased 
stress had longer distances to their rheumatologists 
compared with patients who reported that medical care 
transportation did not cause them more stress, but this 
finding did not reach statistical significance (P 0.055 
in Fig.  2). There were significant differences (P  <  0.05) 
Table 1 Demographic characteristics of SLE travel burden 
survey participants (N = 39)
Self-rated health status was assessed with the following question: in general, 
what would you say your health is….? [48]
Gender
 Female 33 (84.62 %)
 Male 4 (10.26 %)
 Missing 2 (5.12 %)
Race
 White 13 (32.5 %)
 Black, or African–American 26 (65.0 %)
Age
 Mean (SD) 43.15 (12.92)
 Median (Q1–Q3) 41.5 (32, 49.25)
 Min–max (23, 75)
Education level
 ≤High school 9 (23.08 %)
 ≥College 29 (74.36 %)
 Missing 1 (2.56) 
Employment status
 Employed 21 (53.85 %)
 Other 18 (46.15 %)
Self-evaluated health status
 Good 21 (53.85 %)
 Fair 9 (23.08 %)
 Missing 9 (23.08 %)
Annual household income
 <$15,000 9 (23.08 %)
 Between 19 (48.72 %)
 >$60,000 11 (28.21 %)
Marital status
 Married 15 (38.46 %)
 Never married 6 (15.38 %)
 Other 8 (20.51 %)
 Missing 10 (25.64)
Currently have health insurance
 Yes 36 (92.31 %)
 No 3 (7.69 %)
Primary insurance medicaid
 Yes 9 (23.08 %)
 No 26 (66.67 %)
 Missing 4 (10.26 %)
Primary insurance medicare
 Yes 7 (17.95 %)
 No 19 (48.72 %)
 Missing 13 (33.33 %)
Insurance covering medical transportation
 Yes 9 (23.08 %)
 No 30 (76.92 %)
Table 2 Health-related travel burden of SLE travel burden 
survey participants (N = 39)
Distance to rheumatologist (miles)
 Mean (Std) 52.94 (47.04)
 Median (Q1–Q3) 40 (10–78)
 Min–max 4–200
Travel time to Lupus medical care (minutes)
 Mean (Std) 57.01 (41.67)
 Median (Q1–Q3) 45 (20–90)
 Min–max 4–150
Page 5 of 9Williams et al. BMC Res Notes  (2016) 9:246 
in the distance to rheumatologists and time to lupus 
medical care for those participants who reported dif-
ficulties in keeping medical appointments as a result of 
travel burdens, compared with those who reported no 
difficulty. Usually, participants reporting difficulty keep-
ing medical appointments had longer distances to their 
rheumatologists and spent more time getting to lupus 
medical care (Fig.  3a, b). Similarly, for those partici-
pants who noted difficulties with medical care travel, sig-
nificant differences (P  <  0.01) existed in the distance to 
rheumatologists and time to lupus-associated medical 
Table 3 SLE travel burden survey attitude toward medical 
care travel (N = 41)
Do travel issues make keeping your appointments
 Difficult 12 (30.77 %)
 Neither 13 (33.33 %)
 Easy 11 (28.21 %)
 Missing 5 (12.20 %) 
How would you describe travel for medical care travel
 Difficult 15 (36.59 %)
 Neither 8 (19.51 %)
 Easy 17 (43.59 %)
 Missing 1 (2.44 %) 
How difficult is it for you to travel to your primary care provider
 Difficult 8 (19.51 %)
 Neither 7 (17.07 %)
 Easy 25 (60.98 %)
 Missing 1 (2.44 %) 
How difficult is it for you to travel to your rheumatologist
 Difficult 16 (39.02 %)
 Neither 7 (17.07 %)
 Easy 17 (43.59 %)
 Missing 1 (2.44 %)
Table 4 SLE travel burden survey primary outcome vari-
ables (N = 39)
Do you feel travel affects whether you are able to keep your appoint-
ments
 Yes 14 (35.90 %)
 No 25 (64.10 %)
Have travel issues ever resulted in your medications being discontinued 
as a result of missed appointments
 Yes 5 (12.82 %)
 No 34 (87.18 %)
Would you agree that transportation issues for medical care increases 
stress
 Yes 26 (66.67 %)
 No 13 (33.33 %)
In 1 year, how many appointments have you missed/rescheduled 
because of transportation problems
 0 21 (53.85 %)
 1–2 6 (15.38 %)
 3–5 11 (28.21 %)
 Missing 1 (2.56 %)
Fig. 1 Travel affects appointments
Fig. 2 Medical care transportation increases stress
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care. Again, most participants reporting difficulty with 
medical care travel had longer distances to their rheuma-
tologists and spent more time getting to lupus-associated 
medical care (Fig. 4a, b). There were no significant differ-
ences (P > 0.05), for participants who reported difficulties 
with primary care travel, in the distance to rheumatolo-
gists and time to lupus-associated medical care (Fig. 5a, 
b). For those participants who reported difficulties with 
travel to their rheumatologist, significant differences 
(P < 0.05) existed in the distance to rheumatologists and 
time to lupus-associated medical care. Both distance to 
rheumatologists and time to lupus-associated medical 
care were significant at level 0.1 in unadjusted regres-
sion models with outcomes of whether travel affected 
appointments and number of appointments missed due 
to transportation issues, but they became insignificant 
after adjustment for health status, income level, and car 
ownership. Both distance and time to medical care were 
not significant with outcomes of medication discontinu-
ation and transportation issues increasing stress, in both 
unadjusted and adjusted logistic regression models. (see 
Table 5).
Discussion
Further study could include utilizing GIS techniques to 
characterize such travel burden by comparing self-rated 
travel burden (e.g., travel distance for healthcare, travel 
costs for healthcare) with actual travel burden (e.g., uti-
lizing place of residence and facility address to map travel 
distances). These techniques are valuable in understand-
ing the expanded scope of barriers to include SLE health-
related travel [43]. Taxi-cab distance measures could be 
calculated in ArcMap to provide travel times.
There is also a critical gap in our understanding of 
urban/rural differences in travel burden among SLE 
patients. Due to incomplete responses, we were unable 
to present and analyze information on urban vs. rural 
residence. However, South Carolina provides the ideal 
environment for study and future inquiries are planned. 
Utilizing the MUSC SLE Database, which includes 
patients across the state of South Carolina, provides a 
unique opportunity to characterize urban/rural issues 
that may not be permitted in other cohort studies that are 
mainly organized in urban areas. While it is recognized 
that interviewees may not be nationally representative, 
Fig. 3 Difficulty for keeping appointments
Fig. 4 Difficulty for medical care travel
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this population could provide us with knowledge pertain-
ing to South Carolina and its uniqueness in urban/rural 
divisions, and lead to broader application to other areas 
with significant rural populations. Interestingly a major-
ity of respondents had health insurance, which greatly 
varies from nationally representative studies among SLE 
patients which demonstrates that many SLE patients have 
public insurance (e.g., Medicaid) [44]. Although it should 
be noted that insurance rates in our sample (roughly 25 % 
Medicaid beneficiaries, and roughly 26 % of participants 
were Medicare beneficiaries) were comparable to state 
analyses of SLE patients (roughly 55 % SLE patients had 
public insurance) [45]. Most of the participants identified 
that their public insurance had associated support for 
medical transportation, which varies greatly compared to 
most persons nationally [46].
Other limitations of the current study include limited 
information provided on the nature of the sample, par-
ticularly SLE disease characteristics and a small sample 
size limiting the ability to perform significant modelling 
or data exploration. It is crucial that other groups col-
laborate in validating the survey instrument in external 
cohorts to confirm and further support our findings and 
conclusions. Future directions could include characteri-
zation of the role of residence and how observed trends 
may vary buy rurality/urbanity. In one study, rural resi-
dents on average traveled eight miles farther than urban 
residents. The study further states that it also took Afri-
can–Americans more time to get to their provider com-
pared to their white counterparts [47] but it does not 
specifically address individuals with SLE and the type of 
specialist care that is necessary in that context.
Conclusions
Our findings indicate that medical transportation 
increased stress for most participants. Travel burden 
pertaining to distance and time shows that longer dis-
tance and time are associated with negative outcomes 
like increased pressure on medical appointments and 
causing medications to be discontinued or appointments 
Fig. 5 Difficulty for primary care travel
Table 5 Unadjusted and adjusted models of the effects of travel on appointments
Adjusted model adjusted for age, gender, education level, employment status, self-evaluated health status, annual household income, and marital status
* Level of significance P < 0.05 for each category
Outcome: travel affects appointments Unadjusted model Adjusted model
Predictor Estimate Std. error P value Estimate Std. error P value
Time to lupus medical care 0.022 0.010 0.019* 0.218 0.239 0.36
Distance to rheumatologists 0.015 0.008 0.069* 0.031 0.035 0.368
Outcome: travel discontinued medications
 Time to lupus medical care 0.013 0.011 0.269 −0.003 0.023 0.908
 Distance to rheumatologists 0.004 0.010 0.647 −0.009 0.023 0.68
Outcome: medical care transportation increases stress
 Time to lupus medical care 0.010 0.009 0.263 0.354 0.337 0.293
 Distance to rheumatologists 0.014 0.009 0.147 0.061 0.067 0.362
Outcome: number of appointments missed due to transportation
 Time to lupus medical care 0.008 0.003 0.014* 0.006 0.014 0.635
 Distance to rheumatologists 0.005 0.003 0.070* 0.001 0.01 0.958
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to be missed. Travel burden needs to be studied exten-
sively with the understanding that the burden is based 
on the perspective of the individual. Particularly, this 
data could inform development of interventions aimed 
at assisting SLE patients with management of stress-
ors related to travel. This project will also provide an 
opportunity for physicians, academic researchers, and 
other health professionals in South Carolina and other 
areas with significant rural populations to gain a better 
understanding of how travel burden may impact patients 
receiving care for SLE, while also informing much 
broader contexts of how to improve participation of SLE 
patients in future studies.
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